This study is in progress, not accepting new patients
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Summary
- Eligibility
- for people ages 16 years and up (full criteria)
- Location
- at UCLA UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Madhav Vissa (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Madhav Vissa (ucsf)
I am a pediatric hematologist with a special interest in caring for individuals with inherited blood disorders, specifically sickle cell disease and thalassemia, throughout the lifespan.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Agios Pharmaceuticals, Inc.
- ID
- NCT05031780
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- About 286 people participating
- Last Updated